In vitro cellular drug sensitivity at diagnosis is correlated to minimal residual disease at end of induction therapy in childhood acute lymphoblastic leukemia

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Abstract

Leukemic cells from 85 children with newly diagnosed precursor B-lineage ALL were tested for in vitro drug sensitivity to a panel of anti-cancer drugs. Minimal residual disease (MRD) was measured by RQ-PCR. There was a significant correlation between MRD day 29 and in vitro sensitivity to prednisolone (p < 0.001) and doxorubicin (p = 0.01 7), drugs administered during induction therapy. In patients with t(12;21) (n = 20), in vitro sensitivity to doxorubicin was an independent factor for MRD <0.1% (p = 0.031; R-2 = 0.66). Thus, data show that in vitro drug sensitivity at diagnosis is correlated to cell kill during induction therapy as measured by MRD day 29. (C) 2008 Elsevier Ltd. All rights reserved.

Detaljer

Författare
  • Gudmar Lonnerholm
  • Ingrid Thorn
  • Christer Sundstrom
  • Britt-Marie Frost
  • Jonas Abrahamsson
  • Mikael Behrendtz
  • Jesper Heldrup
  • Stefan Jacobsson
  • AiHong Li
  • Tor Olofsson
  • Anna Porwit
  • Stefan Soderhall
  • Rolf Larsson
  • Erik Forestier
Enheter & grupper
Forskningsområden

Ämnesklassifikation (UKÄ) – OBLIGATORISK

  • Cancer och onkologi

Nyckelord

Originalspråkengelska
Sidor (från-till)46-53
TidskriftLeukemia Research: A Forum for Studies on Leukemia and Normal Hemopoiesis
Volym33
Utgivningsnummer1
StatusPublished - 2009
PublikationskategoriForskning
Peer review utfördJa